Financial Data and Key Metrics Changes - The company reported a record quarterly cash receipts of AUD 22.4 million, contributing to a positive operating cash flow of AUD 7.4 million for the quarter, marking the strongest result in any quarter for the business [8][10] - For FY25, the company generated a positive operating cash flow of AUD 5.8 million, a significant improvement compared to the negative operating cash flow of AUD 7.1 million in FY24 [10] - The EBITDA guidance for FY25 was upgraded to exceed AUD 4.5 million, indicating strong financial performance [5][15] Business Line Data and Key Metrics Changes - The company achieved new sales with a combined total contract value (TCV) of AUD 6.7 million in Q4, with approximately 73% being recurring product revenues [6][7] - The total TCV sales for FY25 reached AUD 73.8 million, representing a 109% increase compared to the prior calendar period, marking a record for the business [6][7] Market Data and Key Metrics Changes - The company noted significant sales activity in Q4, with ongoing positive market opportunities, particularly in the UK and Australia [20][24] - There is an increasing demand for technology to assist with patient flow and hospital in the home solutions, indicating a favorable market environment for the company's offerings [24][31] Company Strategy and Development Direction - The company is focused on expanding its customer base and enhancing existing customer relationships through contract expansions and upselling new modules [4][15] - The strategic emphasis is on addressing the challenges faced by healthcare systems globally, particularly as populations age and healthcare demands increase [5][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's unique solutions to tackle healthcare challenges and the ability to grow and expand capabilities with customers [5][15] - The company anticipates continued positive activity in the market, with a solid pipeline of implementation projects and new sales opportunities [16][20] Other Important Information - The company has no debt and reported cash reserves of AUD 17.7 million as of June 30 [10] - The implementation phase for significant contracts, such as North Cumbria, is progressing well, with expectations for completion in approximately 18 months [12][16] Q&A Session Summary Question: Update on Hume, Nalan, and Bayside sales - Management indicated significant sales in Q4 but noted that not all sales are individually announceable due to ASX regulations [18][19] Question: Tender opportunities in the UK - There is ongoing tender activity in the UK, with the company actively bidding where it has a competitive edge [21][22] Question: Delays in UK implementations - Delays in UHS deployment are primarily due to the transition from one system to another, while Tameside's delays are due to resource constraints on their end [25][26] Question: Revenue composition and cost base - Implementation revenue constitutes 27% of Q4 new sales, with around 15% of the staff working directly on delivery projects [27][28] Question: Update on US partnership with Genie Solaire - The partnership is focused on a go-to-market strategy for the Middle East, with potential US opportunities being explored [28] Question: Impact of NHS digital health funding - There is a continued commitment to digitization in the NHS, with tenders still coming to market [29] Question: Increased spending on enterprise health tech in Australia - There is an uptick in investment in digital health solutions in Australia, particularly in WA and Tasmania [31][32] Question: Upfront capital license receipts for North Cumbria - The upfront capital license receipt for North Cumbria is approximately AUD 8 million, received in the quarter [33] Question: Status of NHS trust APR decisions - The status of APR decisions is not known until the company is informed of being a preferred provider [35] Question: Revenue reliance on the UK and Australia - The company has a balanced revenue stream from the UK and ANZ, while exploring opportunities in Canada, the Middle East, and Southeast Asia [42][43]